{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:40:10Z","timestamp":1784544010944,"version":"3.55.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Project of Scientific Research and Innovation Programme of Shandong Second Medical University","award":["2024BKQ040"],"award-info":[{"award-number":["2024BKQ040"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-84942-8","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T08:24:17Z","timestamp":1736929457000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A network meta-analysis of therapies for hyperphosphatemia in CKD based on randomized trials"],"prefix":"10.1038","volume":"15","author":[{"given":"Congyang","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"84942_CR1","doi-asserted-by":"publisher","first-page":"352","DOI":"10.34067\/kid.0000000000000374","volume":"5","author":"N Tangri","year":"2024","unstructured":"Tangri, N. et al. Mortality, health care burden, and treatment of CKD: A multinational, observational study (OPTIMISE-CKD). Kidney360 5, 352\u2013362. https:\/\/doi.org\/10.34067\/kid.0000000000000374 (2024).","journal-title":"Kidney360"},{"key":"84942_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","volume":"20","author":"A Francis","year":"2024","unstructured":"Francis, A. et al. Chronic kidney disease and the global public health agenda: An international consensus. Nat. Rev. Nephrol. 20, 473\u2013485. https:\/\/doi.org\/10.1038\/s41581-024-00820-6 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"84942_CR3","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jama.2019.14745","volume":"322","author":"TK Chen","year":"2019","unstructured":"Chen, T. K., Knicely, D. H. & Grams, M. E. Chronic kidney disease diagnosis and management: A review. Jama 322, 1294\u20131304. https:\/\/doi.org\/10.1001\/jama.2019.14745 (2019).","journal-title":"Jama"},{"key":"84942_CR4","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.kint.2017.11.036","volume":"93","author":"MG Vervloet","year":"2018","unstructured":"Vervloet, M. G. & van Ballegooijen, A. J. Prevention and treatment of hyperphosphatemia in chronic kidney disease. Kidney Int. 93, 1060\u20131072. https:\/\/doi.org\/10.1016\/j.kint.2017.11.036 (2018).","journal-title":"Kidney Int."},{"key":"84942_CR5","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.kint.2021.01.016","volume":"99","author":"C Zhou","year":"2021","unstructured":"Zhou, C. et al. Hyperphosphatemia in chronic kidney disease exacerbates atherosclerosis via a mannosidases-mediated complex-type conversion of SCAP N-glycans. Kidney Int. 99, 1342\u20131353. https:\/\/doi.org\/10.1016\/j.kint.2021.01.016 (2021).","journal-title":"Kidney Int."},{"key":"84942_CR6","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.kint.2015.12.046","volume":"89","author":"NJ Paloian","year":"2016","unstructured":"Paloian, N. J., Leaf, E. M. & Giachelli, C. M. Osteopontin protects against high phosphate-induced nephrocalcinosis and vascular calcification. Kidney Int. 89, 1027\u20131036. https:\/\/doi.org\/10.1016\/j.kint.2015.12.046 (2016).","journal-title":"Kidney Int."},{"key":"84942_CR7","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2016.03.039","volume":"90","author":"H Komaba","year":"2016","unstructured":"Komaba, H. & Fukagawa, M. Phosphate-a poison for humans?. Kidney Int. 90, 753\u2013763. https:\/\/doi.org\/10.1016\/j.kint.2016.03.039 (2016).","journal-title":"Kidney Int."},{"key":"84942_CR8","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1161\/atvbaha.123.319198","volume":"44","author":"ME Turner","year":"2024","unstructured":"Turner, M. E. et al. Phosphate in cardiovascular disease: From new insights into molecular mechanisms to clinical implications. Arterioscler. Thromb. Vasc. Biol. 44, 584\u2013602. https:\/\/doi.org\/10.1161\/atvbaha.123.319198 (2024).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"84942_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.freeradbiomed.2020.01.024","volume":"157","author":"T Nakanishi","year":"2020","unstructured":"Nakanishi, T., Nanami, M. & Kuragano, T. The pathogenesis of CKD complications; Attack of dysregulated iron and phosphate metabolism. Free Radic. Biol. Med. 157, 55\u201362. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2020.01.024 (2020).","journal-title":"Free Radic. Biol. Med."},{"key":"84942_CR10","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.ekir.2022.01.1055","volume":"7","author":"SM Doshi","year":"2022","unstructured":"Doshi, S. M. & Wish, J. B. Past, present, and future of phosphate management. Kidney Int. Rep. 7, 688\u2013698. https:\/\/doi.org\/10.1016\/j.ekir.2022.01.1055 (2022).","journal-title":"Kidney Int. Rep."},{"key":"84942_CR11","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/sdi.12411","volume":"28","author":"AJ Felsenfeld","year":"2015","unstructured":"Felsenfeld, A. J., Levine, B. S. & Rodriguez, M. Pathophysiology of calcium, phosphorus, and magnesium dysregulation in chronic kidney disease. Semin. Dial. 28, 564\u2013577. https:\/\/doi.org\/10.1111\/sdi.12411 (2015).","journal-title":"Semin. Dial."},{"key":"84942_CR12","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1053\/j.ajkd.2020.05.025","volume":"77","author":"JJ Scialla","year":"2021","unstructured":"Scialla, J. J. et al. State-of-the-art management of hyperphosphatemia in patients with CKD: An NKF-KDOQI controversies perspective. Am. J. Kidney Dis. 77, 132\u2013141. https:\/\/doi.org\/10.1053\/j.ajkd.2020.05.025 (2021).","journal-title":"Am. J. Kidney Dis."},{"key":"84942_CR13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s40620-019-00689-w","volume":"33","author":"J Floege","year":"2020","unstructured":"Floege, J. Phosphate binders in chronic kidney disease: An updated narrative review of recent data. J. Nephrol. 33, 497\u2013508. https:\/\/doi.org\/10.1007\/s40620-019-00689-w (2020).","journal-title":"J. Nephrol."},{"key":"84942_CR14","doi-asserted-by":"publisher","first-page":"440","DOI":"10.2215\/cjn.05130610","volume":"6","author":"KJ Martin","year":"2011","unstructured":"Martin, K. J. & Gonz\u00e1lez, E. A. Prevention and control of phosphate retention\/hyperphosphatemia in CKD-MBD: What is normal, when to start, and how to treat?. Clin. J. Am. Soc. Nephrol. 6, 440\u2013446. https:\/\/doi.org\/10.2215\/cjn.05130610 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"84942_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1159\/000534484","volume":"54","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Efficacy and safety of ferric citrate on hyperphosphatemia among Chinese patients with chronic kidney disease undergoing hemodialysis: A phase III multicenter randomized open-label active-drug-controlled study. Am. J. Nephrol. 54, 479\u2013488. https:\/\/doi.org\/10.1159\/000534484 (2023).","journal-title":"Am. J. Nephrol."},{"key":"84942_CR16","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.clinthera.2021.03.025","volume":"43","author":"D van de Groenendaal Meent","year":"2021","unstructured":"van de Groenendaal Meent, D. et al. Effect of the phosphate binders sevelamer carbonate and calcium acetate on the pharmacokinetics of roxadustat after concomitant or time-separated administration in healthy individuals. Clin. Ther. 43, 1079\u20131091. https:\/\/doi.org\/10.1016\/j.clinthera.2021.03.025 (2021).","journal-title":"Clin. Ther."},{"key":"84942_CR17","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40262-020-00974-z","volume":"60","author":"D Reki\u0107","year":"2021","unstructured":"Reki\u0107, D. et al. Pharmacokinetics of roxadustat: A population analysis of 2855 dialysis- and non-dialysis-dependent patients with chronic kidney disease. Clin. Pharmacokinet. 60, 759\u2013773. https:\/\/doi.org\/10.1007\/s40262-020-00974-z (2021).","journal-title":"Clin. Pharmacokinet."},{"key":"84942_CR18","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ndt\/gfaa010","volume":"35","author":"C Ginsberg","year":"2020","unstructured":"Ginsberg, C. et al. Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease. Nephrol. Dial. Transplant. 35, 616\u2013623. https:\/\/doi.org\/10.1093\/ndt\/gfaa010 (2020).","journal-title":"Nephrol. Dial. Transplant."},{"key":"84942_CR19","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3390\/toxins13100688","volume":"13","author":"K Takkavatakarn","year":"2021","unstructured":"Takkavatakarn, K. et al. Protein-bound uremic toxins lowering effect of sevelamer in pre-dialysis chronic kidney disease patients with hyperphosphatemia: A randomized controlled trial. Toxins 13, 688. https:\/\/doi.org\/10.3390\/toxins13100688 (2021).","journal-title":"Toxins"},{"key":"84942_CR20","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/hdi.12663","volume":"22","author":"SM Sprague","year":"2018","unstructured":"Sprague, S. M. et al. Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients. Hemodial. Int. 22, 480\u2013491. https:\/\/doi.org\/10.1111\/hdi.12663 (2018).","journal-title":"Hemodial. Int."},{"key":"84942_CR21","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1001\/jama.2021.4807","volume":"325","author":"H Ogata","year":"2021","unstructured":"Ogata, H. et al. Effect of treating hyperphosphatemia with lanthanum carbonate vs calcium carbonate on cardiovascular events in patients with chronic kidney disease undergoing hemodialysis: The LANDMARK randomized clinical trial. Jama 325, 1946\u20131954. https:\/\/doi.org\/10.1001\/jama.2021.4807 (2021).","journal-title":"Jama"},{"key":"84942_CR22","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/ndt\/gfy127","volume":"34","author":"M Ketteler","year":"2019","unstructured":"Ketteler, M. et al. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients. Nephrol. Dial. Transplant. 34, 1163\u20131170. https:\/\/doi.org\/10.1093\/ndt\/gfy127 (2019).","journal-title":"Nephrol. Dial. Transplant."},{"key":"84942_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40620-018-00571-1","volume":"32","author":"Y Gao","year":"2019","unstructured":"Gao, Y., Wang, G., Li, Y., Lv, C. & Wang, Z. Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3\u20134 chronic kidney disease. J. Nephrol. 32, 265\u2013272. https:\/\/doi.org\/10.1007\/s40620-018-00571-1 (2019).","journal-title":"J. Nephrol."},{"key":"84942_CR24","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1053\/j.ajkd.2015.03.013","volume":"66","author":"PN Van Buren","year":"2015","unstructured":"Van Buren, P. N. et al. The phosphate binder ferric citrate and mineral metabolism and inflammatory markers in maintenance dialysis patients: Results from prespecified analyses of a randomized clinical trial. Am. J. Kidney Dis. 66, 479\u2013488. https:\/\/doi.org\/10.1053\/j.ajkd.2015.03.013 (2015).","journal-title":"Am. J. Kidney Dis."},{"key":"84942_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12882-016-0245-3","volume":"17","author":"HH Lin","year":"2016","unstructured":"Lin, H. H., Liou, H. H., Wu, M. S. & Huang, C. C. Factors associated with serum fetuin-A concentrations after long-term use of different phosphate binders in hemodialysis patients. BMC Nephrol. 17, 33. https:\/\/doi.org\/10.1186\/s12882-016-0245-3 (2016).","journal-title":"BMC Nephrol."},{"key":"84942_CR26","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1007\/s10157-016-1362-9","volume":"21","author":"YM Chang","year":"2017","unstructured":"Chang, Y. M. et al. Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients. Clin. Exp. Nephrol. 21, 908\u2013916. https:\/\/doi.org\/10.1007\/s10157-016-1362-9 (2017).","journal-title":"Clin. Exp. Nephrol."},{"key":"84942_CR27","doi-asserted-by":"publisher","first-page":"c83","DOI":"10.1159\/000319654","volume":"117","author":"M Boaz","year":"2011","unstructured":"Boaz, M. et al. Effect of sevelamer hydrochloride exposure on carotid intima media thickness in hemodialysis patients. Nephron Clin. Pract. 117, c83-88. https:\/\/doi.org\/10.1159\/000319654 (2011).","journal-title":"Nephron Clin. Pract."},{"key":"84942_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40620-014-0071-2","volume":"28","author":"D Russo","year":"2015","unstructured":"Russo, D., Bellasi, A., Pota, A., Russo, L. & Di Iorio, B. Effects of phosphorus-restricted diet and phosphate-binding therapy on outcomes in patients with chronic kidney disease. J. Nephrol. 28, 73\u201380. https:\/\/doi.org\/10.1007\/s40620-014-0071-2 (2015).","journal-title":"J. Nephrol."},{"key":"84942_CR29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/1744-9987.12399","volume":"20","author":"K Tsuchida","year":"2016","unstructured":"Tsuchida, K., Nagai, K., Yokota, N., Minakuchi, J. & Kawashima, S. Impact of lanthanum carbonate on prognosis of chronic hemodialysis patients: A retrospective cohort study (Kawashima Study). Ther. Apher. Dial. 20, 142\u2013148. https:\/\/doi.org\/10.1111\/1744-9987.12399 (2016).","journal-title":"Ther. Apher. Dial."},{"key":"84942_CR30","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1681\/asn.2020050598","volume":"32","author":"Y Isaka","year":"2021","unstructured":"Isaka, Y. et al. Optimal phosphate control related to coronary artery calcification in dialysis patients. J. Am. Soc. Nephrol. 32, 723\u2013735. https:\/\/doi.org\/10.1681\/asn.2020050598 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"84942_CR31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40268-015-0103-y","volume":"15","author":"RA Rodby","year":"2015","unstructured":"Rodby, R. A. et al. Ferric citrate, an iron-based phosphate binder, reduces health care costs in patients on dialysis based on randomized clinical trial data. Drugs R D 15, 271\u2013279. https:\/\/doi.org\/10.1007\/s40268-015-0103-y (2015).","journal-title":"Drugs R D"},{"key":"84942_CR32","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2215\/cjn.07750814","volume":"10","author":"EM Yubero-Serrano","year":"2015","unstructured":"Yubero-Serrano, E. M., Woodward, M., Poretsky, L., Vlassara, H. & Striker, G. E. Effects of sevelamer carbonate on advanced glycation end products and antioxidant\/pro-oxidant status in patients with diabetic kidney disease. Clin. J. Am. Soc. Nephrol. 10, 759\u2013766. https:\/\/doi.org\/10.2215\/cjn.07750814 (2015).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"84942_CR33","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00467-020-04805-y","volume":"36","author":"LA Greenbaum","year":"2021","unstructured":"Greenbaum, L. A. et al. Safety and efficacy of sucroferric oxyhydroxide in pediatric patients with chronic kidney disease. Pediatr. Nephrol. 36, 1233\u20131244. https:\/\/doi.org\/10.1007\/s00467-020-04805-y (2021).","journal-title":"Pediatr. Nephrol."},{"key":"84942_CR34","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/nep.12319","volume":"19","author":"HH Lin","year":"2014","unstructured":"Lin, H. H., Liou, H. H., Wu, M. S., Lin, C. Y. & Huang, C. C. Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients. Nephrology 19, 672\u2013678. https:\/\/doi.org\/10.1111\/nep.12319 (2014).","journal-title":"Nephrology"},{"key":"84942_CR35","doi-asserted-by":"publisher","first-page":"191","DOI":"10.5414\/cn108227","volume":"82","author":"KR Phelps","year":"2014","unstructured":"Phelps, K. R., Stote, K. S. & Mason, D. Use of sevelamer to examine the role of intraluminal phosphate in the pathogenesis of secondary hyperparathyroidism. Clin. Nephrol. 82, 191\u2013201. https:\/\/doi.org\/10.5414\/cn108227 (2014).","journal-title":"Clin. Nephrol."},{"key":"84942_CR36","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.clinthera.2014.06.036","volume":"36","author":"MS Keith","year":"2014","unstructured":"Keith, M. S., Wilson, R. J., Preston, P. & Copley, J. B. Cost-minimization analysis of lanthanum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease. Clin. Ther. 36, 1276\u20131286. https:\/\/doi.org\/10.1016\/j.clinthera.2014.06.036 (2014).","journal-title":"Clin. Ther."},{"key":"84942_CR37","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40620-014-0122-8","volume":"28","author":"M Ruggeri","year":"2015","unstructured":"Ruggeri, M. et al. Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: A patient-level economic evaluation of the INDEPENDENT-HD study. J. Nephrol. 28, 593\u2013602. https:\/\/doi.org\/10.1007\/s40620-014-0122-8 (2015).","journal-title":"J. Nephrol."},{"key":"84942_CR38","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1471-2369-15-98","volume":"15","author":"T Akizawa","year":"2014","unstructured":"Akizawa, T. et al. Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: A multi-center, randomized, double-blind, placebo-controlled trial. BMC Nephrol. 15, 98. https:\/\/doi.org\/10.1186\/1471-2369-15-98 (2014).","journal-title":"BMC Nephrol."},{"key":"84942_CR39","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40261-014-0206-1","volume":"34","author":"D Padhi","year":"2014","unstructured":"Padhi, D., Harris, R. & Sullivan, J. T. Effects of calcium carbonate, sevelamer hydrochloride or pantoprazole on the pharmacokinetics of cinacalcet. Clin. Drug Investig. 34, 537\u2013544. https:\/\/doi.org\/10.1007\/s40261-014-0206-1 (2014).","journal-title":"Clin. Drug Investig."},{"key":"84942_CR40","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/ki.2014.58","volume":"86","author":"J Floege","year":"2014","unstructured":"Floege, J. et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 86, 638\u2013647. https:\/\/doi.org\/10.1038\/ki.2014.58 (2014).","journal-title":"Kidney Int."},{"key":"84942_CR41","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s12325-013-0077-5","volume":"30","author":"RJ Wilson","year":"2013","unstructured":"Wilson, R. J., Keith, M. S., Preston, P. & Copley, J. B. The real-world dose-relativity of sevelamer hydrochloride and lanthanum carbonate monotherapy in patients with end-stage renal disease. Adv. Ther. 30, 1100\u20131110. https:\/\/doi.org\/10.1007\/s12325-013-0077-5 (2013).","journal-title":"Adv. Ther."},{"key":"84942_CR42","doi-asserted-by":"publisher","first-page":"F61","DOI":"10.1152\/ajprenal.00219.2013","volume":"306","author":"GJ Behets","year":"2014","unstructured":"Behets, G. J. et al. Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders. Am. J. Physiol. Renal Physiol. 306, F61-67. https:\/\/doi.org\/10.1152\/ajprenal.00219.2013 (2014).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"84942_CR43","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/ndt\/gft232","volume":"29","author":"N Chen","year":"2014","unstructured":"Chen, N. et al. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: A randomized, double-blind, placebo-controlled, dose-titration study. Nephrol. Dial. Transplant. 29, 152\u2013160. https:\/\/doi.org\/10.1093\/ndt\/gft232 (2014).","journal-title":"Nephrol. Dial. Transplant."},{"key":"84942_CR44","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1681\/asn.2020040411","volume":"31","author":"ND Toussaint","year":"2020","unstructured":"Toussaint, N. D. et al. A randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD). J. Am. Soc. Nephrol. 31, 2653\u20132666. https:\/\/doi.org\/10.1681\/asn.2020040411 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"84942_CR45","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10157-016-1310-8","volume":"21","author":"H Ogata","year":"2017","unstructured":"Ogata, H. et al. Design and baseline characteristics of the LANDMARK study. Clin. Exp. Nephrol. 21, 531\u2013537. https:\/\/doi.org\/10.1007\/s10157-016-1310-8 (2017).","journal-title":"Clin. Exp. Nephrol."},{"key":"84942_CR46","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1093\/ndt\/gft203","volume":"28","author":"A Covic","year":"2013","unstructured":"Covic, A. et al. A comparison of calcium acetate\/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: Post hoc evaluation from a controlled, randomized study. Nephrol. Dial. Transplant. 28, 2383\u20132392. https:\/\/doi.org\/10.1093\/ndt\/gft203 (2013).","journal-title":"Nephrol. Dial. Transplant."},{"key":"84942_CR47","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.2215\/cjn.04100609","volume":"4","author":"WL St Peter","year":"2009","unstructured":"St Peter, W. L., Fan, Q., Weinhandl, E. & Liu, J. Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: A secondary analysis using centers for Medicare & Medicaid services data. Clin. J. Am. Soc. Nephrol. 4, 1954\u20131961. https:\/\/doi.org\/10.2215\/cjn.04100609 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"84942_CR48","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1681\/asn.2018101016","volume":"30","author":"GA Block","year":"2019","unstructured":"Block, G. A. et al. A pilot randomized trial of ferric citrate coordination complex for the treatment of advanced CKD. J. Am. Soc. Nephrol. 30, 1495\u20131504. https:\/\/doi.org\/10.1681\/asn.2018101016 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"84942_CR49","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1681\/asn.2020101398","volume":"32","author":"PE Pergola","year":"2021","unstructured":"Pergola, P. E., Rosenbaum, D. P., Yang, Y. & Chertow, G. M. A randomized trial of tenapanor and phosphate binders as a dual-mechanism treatment for hyperphosphatemia in patients on maintenance dialysis (AMPLIFY). J. Am. Soc. Nephrol. 32, 1465\u20131473. https:\/\/doi.org\/10.1681\/asn.2020101398 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"84942_CR50","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/ndt\/gft483","volume":"29","author":"K Yokoyama","year":"2014","unstructured":"Yokoyama, K. et al. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol. Dial. Transplant. 29, 1053\u20131060. https:\/\/doi.org\/10.1093\/ndt\/gft483 (2014).","journal-title":"Nephrol. Dial. Transplant."},{"issue":"Suppl 2","key":"84942_CR51","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/1744-9987.12202","volume":"18","author":"T Akizawa","year":"2014","unstructured":"Akizawa, T., Origasa, H., Kameoka, C., Kaneko, Y. & Kanoh, H. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: A double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study. Ther. Apher. Dial. 18(Suppl 2), 24\u201332. https:\/\/doi.org\/10.1111\/1744-9987.12202 (2014).","journal-title":"Ther. Apher. Dial."},{"key":"84942_CR52","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1053\/j.ajkd.2012.11.041","volume":"61","author":"JP Dwyer","year":"2013","unstructured":"Dwyer, J. P. et al. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: A short-term randomized trial. Am. J. Kidney Dis. 61, 759\u2013766. https:\/\/doi.org\/10.1053\/j.ajkd.2012.11.041 (2013).","journal-title":"Am. J. Kidney Dis."},{"key":"84942_CR53","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/1744-9987.12178","volume":"18","author":"Y Wei","year":"2014","unstructured":"Wei, Y., Kong, X. L., Li, W. B. & Wang, Z. S. Effect of calcium carbonate combined with calcitonin on hypercalcemia in hemodialysis patients. Ther. Apher. Dial. 18, 618\u2013622. https:\/\/doi.org\/10.1111\/1744-9987.12178 (2014).","journal-title":"Ther. Apher. Dial."},{"key":"84942_CR54","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40620-014-0108-6","volume":"28","author":"CT Lee","year":"2015","unstructured":"Lee, C. T. et al. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: Multicenter, randomized, double-blind, placebo-controlled study. J. Nephrol. 28, 105\u2013113. https:\/\/doi.org\/10.1007\/s40620-014-0108-6 (2015).","journal-title":"J. Nephrol."},{"key":"84942_CR55","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/ndt\/gfw042","volume":"32","author":"A Lenglet","year":"2017","unstructured":"Lenglet, A. et al. Efficacy and safety of nicotinamide in haemodialysis patients: The NICOREN study. Nephrol. Dial. Transplant. 32, 870\u2013879. https:\/\/doi.org\/10.1093\/ndt\/gfw042 (2017).","journal-title":"Nephrol. Dial. Transplant."},{"key":"84942_CR56","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/nep.12891","volume":"22","author":"F Koiwa","year":"2017","unstructured":"Koiwa, F., Yokoyama, K., Fukagawa, M., Terao, A. & Akizawa, T. Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study. Nephrology 22, 293\u2013300. https:\/\/doi.org\/10.1111\/nep.12891 (2017).","journal-title":"Nephrology"},{"key":"84942_CR57","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1681\/asn.2018080832","volume":"30","author":"GA Block","year":"2019","unstructured":"Block, G. A., Rosenbaum, D. P., Yan, A. & Chertow, G. M. Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: A randomized phase 3 trial. J. Am. Soc. Nephrol. 30, 641\u2013652. https:\/\/doi.org\/10.1681\/asn.2018080832 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"84942_CR58","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-2369-14-29","volume":"14","author":"J Xu","year":"2013","unstructured":"Xu, J. et al. Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: Multicenter, double blind, randomized, controlled trial in mainland China. BMC Nephrol. 14, 29. https:\/\/doi.org\/10.1186\/1471-2369-14-29 (2013).","journal-title":"BMC Nephrol."},{"key":"84942_CR59","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1093\/ndt\/gfw460","volume":"32","author":"J Floege","year":"2017","unstructured":"Floege, J. et al. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrol. Dial. Transplant. 32, 1918\u20131926. https:\/\/doi.org\/10.1093\/ndt\/gfw460 (2017).","journal-title":"Nephrol. Dial. Transplant."},{"key":"84942_CR60","doi-asserted-by":"publisher","first-page":"8877","DOI":"10.1038\/s41598-019-45335-4","volume":"9","author":"K Yokoyama","year":"2019","unstructured":"Yokoyama, K. et al. Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study. Sci. Rep. 9, 8877. https:\/\/doi.org\/10.1038\/s41598-019-45335-4 (2019).","journal-title":"Sci. Rep."},{"key":"84942_CR61","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2215\/cjn.08230811","volume":"8","author":"RP W\u00fcthrich","year":"2013","unstructured":"W\u00fcthrich, R. P. et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 8, 280\u2013289. https:\/\/doi.org\/10.2215\/cjn.08230811 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"84942_CR62","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/1744-9987.12068","volume":"18","author":"T Akizawa","year":"2014","unstructured":"Akizawa, T., Origasa, H., Kameoka, C., Kaneko, Y. & Kawasaki, S. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia. Ther. Apher. Dial. 18, 122\u2013131. https:\/\/doi.org\/10.1111\/1744-9987.12068 (2014).","journal-title":"Ther. Apher. Dial."},{"key":"84942_CR63","doi-asserted-by":"publisher","first-page":"e0188712","DOI":"10.1371\/journal.pone.0188712","volume":"12","author":"GM Chertow","year":"2017","unstructured":"Chertow, G. M. et al. Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease. PLoS One 12, e0188712. https:\/\/doi.org\/10.1371\/journal.pone.0188712 (2017).","journal-title":"PLoS One"},{"key":"84942_CR64","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.2215\/cjn.05161107","volume":"3","author":"M Ketteler","year":"2008","unstructured":"Ketteler, M. et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin. J. Am. Soc. Nephrol. 3, 1125\u20131130. https:\/\/doi.org\/10.2215\/cjn.05161107 (2008).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"84942_CR65","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1093\/ndt\/gft476","volume":"29","author":"F Locatelli","year":"2014","unstructured":"Locatelli, F. et al. The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: A 1-year prospective randomized study. Nephrol. Dial. Transplant. 29, 1061\u20131073. https:\/\/doi.org\/10.1093\/ndt\/gft476 (2014).","journal-title":"Nephrol. Dial. Transplant."},{"key":"84942_CR66","doi-asserted-by":"publisher","first-page":"33","DOI":"10.16282\/j.cnki.cn11-9336\/r.2017.34.024","volume":"5","author":"C Ren","year":"2017","unstructured":"Ren, C. Observing the efficacy and safety of lanthanum carbonate in the treatment of hyperphosphatemia in uremic maintenance hemodialysis patients. Electron. J. Integr. Cardiovasc. Dis. 5, 33\u201334. https:\/\/doi.org\/10.16282\/j.cnki.cn11-9336\/r.2017.34.024 (2017).","journal-title":"Electron. J. Integr. Cardiovasc. Dis."},{"key":"84942_CR67","doi-asserted-by":"publisher","first-page":"225","DOI":"10.13412\/j.cnki.zyyl.2016.06.064","volume":"32","author":"S Tang","year":"2016","unstructured":"Tang, S. et al. A randomized controlled clinical study of Haimu Hypophosphorus San for the treatment of hyperphosphatemia in hemodialysis patients with stage 5 chronic kidney disease. Chin. Pharmacol. Clin. 32, 225\u2013228. https:\/\/doi.org\/10.13412\/j.cnki.zyyl.2016.06.064 (2016).","journal-title":"Chin. Pharmacol. Clin."},{"key":"84942_CR68","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000351811","volume":"123","author":"C Spatz","year":"2013","unstructured":"Spatz, C., Roe, K., Lehman, E. & Verma, N. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease. Nephron. Clin. Pract. 123, 61\u201366. https:\/\/doi.org\/10.1159\/000351811 (2013).","journal-title":"Nephron. Clin. Pract."},{"key":"84942_CR69","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1053\/j.ajkd.2013.03.023","volume":"62","author":"B Di Iorio","year":"2013","unstructured":"Di Iorio, B. et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: Results of an open-label 24-month randomized clinical trial. Am. J. Kidney Dis. 62, 771\u2013778. https:\/\/doi.org\/10.1053\/j.ajkd.2013.03.023 (2013).","journal-title":"Am. J. Kidney Dis."},{"issue":"Suppl 1","key":"84942_CR70","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/1744-9987.12042","volume":"17","author":"T Ishizu","year":"2013","unstructured":"Ishizu, T., Hong, Z., Matsunaga, T., Kaneko, Y. & Taru, Y. Efficacy of continuous oral administration of lanthanum carbonate over 24 months. Ther. Apher. Dial. 17(Suppl 1), 22\u201328. https:\/\/doi.org\/10.1111\/1744-9987.12042 (2013).","journal-title":"Ther. Apher. Dial."},{"key":"84942_CR71","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.16440\/j.cnki.1674-8166.2019.08.027","volume":"20","author":"H Xiang","year":"2019","unstructured":"Xiang, H. Observation on the efficacy of Sevelamer in the treatment of maintenance hemodialysis with hyperphosphatemia in chronic renal failure. J. Chronic Dis. 20, 1214\u20131215. https:\/\/doi.org\/10.16440\/j.cnki.1674-8166.2019.08.027 (2019).","journal-title":"J. Chronic Dis."},{"key":"84942_CR72","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1755-6686.2013.12009.x","volume":"39","author":"SP Chennasamudram","year":"2013","unstructured":"Chennasamudram, S. P., Noor, T. & Vasylyeva, T. L. Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis. J. Ren. Care 39, 82\u201389. https:\/\/doi.org\/10.1111\/j.1755-6686.2013.12009.x (2013).","journal-title":"J. Ren. Care"},{"key":"84942_CR73","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.16440\/j.cnki.1674-8166.2019.12.020","volume":"20","author":"Y Wang","year":"2019","unstructured":"Wang, Y., Xie, F. & Ye, T. Effectiveness of Sevelamer in the treatment of hemodialysis combined with hyperphosphatemia in chronic renal failure. J. Chronic Dis. 20, 1826\u20131827. https:\/\/doi.org\/10.16440\/j.cnki.1674-8166.2019.12.020 (2019).","journal-title":"J. Chronic Dis."},{"key":"84942_CR74","doi-asserted-by":"publisher","first-page":"183","DOI":"10.16281\/j.cnki.jocml.2019.89.135","volume":"6","author":"Ye Zhu","year":"2019","unstructured":"Zhu, Ye. Clinical efficacy of lanthanum carbonate in the treatment of hyperphosphatemia in uremic maintenance hemodialysis patients. Electron. J. Clin. Med. Lit. 6, 183\u2013184. https:\/\/doi.org\/10.16281\/j.cnki.jocml.2019.89.135 (2019).","journal-title":"Electron. J. Clin. Med. Lit."},{"key":"84942_CR75","doi-asserted-by":"publisher","first-page":"427","DOI":"10.16680\/j.1671-3826.2019.04.39","volume":"47","author":"J Gao","year":"2019","unstructured":"Gao, J., Song, W. W. & Su, Z. G. Effect of sevelamer carbonate on inflammatory factors and calcium and phosphorus metabolism in patients with chronic renal failure combined with hyperphosphatemia. J. Clin. Mil. Med. 47, 427\u2013428. https:\/\/doi.org\/10.16680\/j.1671-3826.2019.04.39 (2019).","journal-title":"J. Clin. Mil. Med."},{"key":"84942_CR76","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1681\/asn.2012030223","volume":"23","author":"GA Block","year":"2012","unstructured":"Block, G. A. et al. Effects of phosphate binders in moderate CKD. J. Am. Soc. Nephrol. 23, 1407\u20131415. https:\/\/doi.org\/10.1681\/asn.2012030223 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"84942_CR77","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1744-9987.2012.01071.x","volume":"16","author":"S Kasai","year":"2012","unstructured":"Kasai, S., Sato, K., Murata, Y. & Kinoshita, Y. Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis. Ther. Apher. Dial. 16, 341\u2013349. https:\/\/doi.org\/10.1111\/j.1744-9987.2012.01071.x (2012).","journal-title":"Ther. Apher. Dial."},{"key":"84942_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5414\/cn106830","volume":"78","author":"RS Kalil","year":"2012","unstructured":"Kalil, R. S., Flanigan, M., Stanford, W. & Haynes, W. G. Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: A prospective pilot study. Clin. Nephrol. 78, 1\u20139. https:\/\/doi.org\/10.5414\/cn106830 (2012).","journal-title":"Clin. Nephrol."},{"key":"84942_CR79","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1007\/s10157-012-0640-4","volume":"16","author":"S Iimori","year":"2012","unstructured":"Iimori, S. et al. Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: A propensity-matched observational study. Clin. Exp. Nephrol. 16, 930\u2013937. https:\/\/doi.org\/10.1007\/s10157-012-0640-4 (2012).","journal-title":"Clin. Exp. Nephrol."},{"key":"84942_CR80","doi-asserted-by":"publisher","first-page":"934","DOI":"10.2215\/cjn.12891211","volume":"7","author":"H Vlassara","year":"2012","unstructured":"Vlassara, H. et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin. J. Am. Soc. Nephrol. 7, 934\u2013942. https:\/\/doi.org\/10.2215\/cjn.12891211 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"84942_CR81","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2215\/cjn.03820411","volume":"7","author":"B Di Iorio","year":"2012","unstructured":"Di Iorio, B., Bellasi, A. & Russo, D. Mortality in kidney disease patients treated with phosphate binders: A randomized study. Clin. J. Am. Soc. Nephrol. 7, 487\u2013493. https:\/\/doi.org\/10.2215\/cjn.03820411 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"84942_CR82","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1542-4758.2011.00575.x","volume":"15","author":"G Jean","year":"2011","unstructured":"Jean, G. et al. Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: Results from the French ARNOS study. Hemodial. Int. 15, 485\u2013492. https:\/\/doi.org\/10.1111\/j.1542-4758.2011.00575.x (2011).","journal-title":"Hemodial. Int."},{"key":"84942_CR83","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1053\/j.ajkd.2010.10.055","volume":"57","author":"T Kakuta","year":"2011","unstructured":"Kakuta, T. et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am. J. Kidney Dis. 57, 422\u2013431. https:\/\/doi.org\/10.1053\/j.ajkd.2010.10.055 (2011).","journal-title":"Am. J. Kidney Dis."},{"key":"84942_CR84","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1053\/j.jrn.2007.10.019","volume":"18","author":"WN Suki","year":"2008","unstructured":"Suki, W. N. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: Results of a randomized clinical trial. J. Ren. Nutr. 18, 91\u201398. https:\/\/doi.org\/10.1053\/j.jrn.2007.10.019 (2008).","journal-title":"J. Ren. Nutr."},{"key":"84942_CR85","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1080\/0886022x.2022.2094273","volume":"44","author":"L Li","year":"2022","unstructured":"Li, L. et al. Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: A meta-analysis of randomized clinical trials. Ren. Fail. 44, 1112\u20131122. https:\/\/doi.org\/10.1080\/0886022x.2022.2094273 (2022).","journal-title":"Ren. Fail."},{"key":"84942_CR86","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1186\/s13063-022-06562-9","volume":"23","author":"EA Vermeulen","year":"2022","unstructured":"Vermeulen, E. A. et al. Reversal of Arterial Disease by modulating Magnesium and Phosphate (ROADMAP-study): Rationale and design of a randomized controlled trial assessing the effects of magnesium citrate supplementation and phosphate-binding therapy on arterial stiffness in moderate chronic kidney disease. Trials 23, 769. https:\/\/doi.org\/10.1186\/s13063-022-06562-9 (2022).","journal-title":"Trials"},{"key":"84942_CR87","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000531869","volume":"148","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer carbonate in Chinese dialysis patients with hyperphosphataemia: A randomised, open-label, multicentre, 12-week phase III study. Nephron 148, 22\u201333. https:\/\/doi.org\/10.1159\/000531869 (2024).","journal-title":"Nephron"},{"key":"84942_CR88","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1053\/j.ajkd.2020.10.003","volume":"77","author":"S Joshi","year":"2021","unstructured":"Joshi, S., McMacken, M. & Kalantar-Zadeh, K. Plant-based diets for kidney disease: A guide for clinicians. Am. J. Kidney Dis. 77, 287\u2013296. https:\/\/doi.org\/10.1053\/j.ajkd.2020.10.003 (2021).","journal-title":"Am. J. Kidney Dis."},{"key":"84942_CR89","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2147\/tcrm.S196805","volume":"16","author":"V Cernaro","year":"2020","unstructured":"Cernaro, V., Calimeri, S., Laudani, A. & Santoro, D. Clinical evaluation of the safety, efficacy and tolerability of lanthanum carbonate in the management of hyperphosphatemia in patients with end-stage renal disease. Ther. Clin. Risk Manag. 16, 871\u2013880. https:\/\/doi.org\/10.2147\/tcrm.S196805 (2020).","journal-title":"Ther. Clin. Risk Manag."},{"key":"84942_CR90","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/ki.2009.60","volume":"75","author":"AJ Hutchison","year":"2009","unstructured":"Hutchison, A. J. Oral phosphate binders. Kidney Int. 75, 906\u2013914. https:\/\/doi.org\/10.1038\/ki.2009.60 (2009).","journal-title":"Kidney Int."},{"key":"84942_CR91","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2215\/cjn.05170513","volume":"9","author":"K Yokoyama","year":"2014","unstructured":"Yokoyama, K. et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin. J. Am. Soc. Nephrol. 9, 543\u2013552. https:\/\/doi.org\/10.2215\/cjn.05170513 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"84942_CR92","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40265-014-0215-7","volume":"74","author":"CM Perry","year":"2014","unstructured":"Perry, C. M. & Plosker, G. L. Sevelamer carbonate: A review in hyperphosphataemia in adults with chronic kidney disease. Drugs 74, 771\u2013792. https:\/\/doi.org\/10.1007\/s40265-014-0215-7 (2014).","journal-title":"Drugs"},{"issue":"Suppl 1","key":"84942_CR93","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.2215\/cjn.05880809","volume":"5","author":"P Raggi","year":"2010","unstructured":"Raggi, P., Vukicevic, S., Moys\u00e9s, R. M., Wesseling, K. & Spiegel, D. M. Ten-year experience with sevelamer and calcium salts as phosphate binders. Clin. J. Am. Soc. Nephrol. 5(Suppl 1), S31-40. https:\/\/doi.org\/10.2215\/cjn.05880809 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"84942_CR94","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nrneph.2016.164","volume":"13","author":"MG Vervloet","year":"2017","unstructured":"Vervloet, M. G. et al. The role of phosphate in kidney disease. Nat. Rev. Nephrol. 13, 27\u201338. https:\/\/doi.org\/10.1038\/nrneph.2016.164 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"84942_CR95","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40265-019-01118-9","volume":"79","author":"A Lenglet","year":"2019","unstructured":"Lenglet, A. et al. Does the administration of sevelamer or nicotinamide modify uremic toxins or endotoxemia in chronic hemodialysis patients?. Drugs 79, 855\u2013862. https:\/\/doi.org\/10.1007\/s40265-019-01118-9 (2019).","journal-title":"Drugs"},{"key":"84942_CR96","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2165\/00003495-200868010-00006","volume":"68","author":"DR Goldsmith","year":"2008","unstructured":"Goldsmith, D. R., Scott, L. J., Cvetkovi\u0107, R. S. & Plosker, G. L. Sevelamer hydrochloride: A review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis. Drugs 68, 85\u2013104. https:\/\/doi.org\/10.2165\/00003495-200868010-00006 (2008).","journal-title":"Drugs"},{"key":"84942_CR97","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1592\/phco.29.5.554","volume":"29","author":"AB Pai","year":"2009","unstructured":"Pai, A. B. & Shepler, B. M. Comparison of sevelamer hydrochloride and sevelamer carbonate: Risk of metabolic acidosis and clinical implications. Pharmacotherapy 29, 554\u2013561. https:\/\/doi.org\/10.1592\/phco.29.5.554 (2009).","journal-title":"Pharmacotherapy"},{"key":"84942_CR98","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1177\/0148607117715440","volume":"42","author":"X Yang","year":"2018","unstructured":"Yang, X. et al. Comparative efficacy and safety of phosphate binders in hyperphosphatemia patients with chronic kidney disease. JPEN J. Parenter. Enteral. Nutr. 42, 766\u2013777. https:\/\/doi.org\/10.1177\/0148607117715440 (2018).","journal-title":"JPEN J. Parenter. Enteral. Nutr."},{"key":"84942_CR99","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2215\/cjn.06800615","volume":"11","author":"L Patel","year":"2016","unstructured":"Patel, L., Bernard, L. M. & Elder, G. J. Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: A meta-analysis of randomized controlled trials. Clin. J. Am. Soc. Nephrol. 11, 232\u2013244. https:\/\/doi.org\/10.2215\/cjn.06800615 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"84942_CR100","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/ndt\/gfw312","volume":"32","author":"S Habbous","year":"2017","unstructured":"Habbous, S. et al. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: A systematic review and meta-analysis. Nephrol. Dial. Transplant. 32, 111\u2013125. https:\/\/doi.org\/10.1093\/ndt\/gfw312 (2017).","journal-title":"Nephrol. Dial. Transplant."},{"key":"84942_CR101","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"KDIGO","year":"2024","unstructured":"KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 105, S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018 (2024).","journal-title":"Kidney Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84942-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84942-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84942-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T08:24:30Z","timestamp":1736929470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84942-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["84942"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-84942-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2012"}}